Plain-English translation of NCT06685042 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a treatment called CD19-CAR Lenti, which uses your own immune cells that have been reprogrammed in a laboratory to fight the cells that cause autoimmune diseases. The treatment is designed for people with serious autoimmune conditions—like lupus, scleroderma, vasculitis, or muscle inflammation—that have not responded well to current standard therapies. You would receive a single infusion of these modified cells, and researchers would monitor how well the medication works and how safe it is.
Some patients with severe autoimmune diseases do not improve even with the best available treatments today, and their conditions can cause life-threatening organ damage. This trial exists because research suggests that reprogramming your own immune cells to target specific harmful B cells could offer hope for people whose disease has not responded to other medications.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo a procedure to collect some of your own immune cells, which would then be sent to a laboratory to be reprogrammed over several weeks. Once ready, you would receive a single intravenous infusion (injection into a vein) of the modified cells. After that, you would have regular follow-up visits and blood tests over the course of at least one year so the research team can monitor whether the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Italy